BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 32 CNY 3.59% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

BrightGene Bio-Medical Technology Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

BrightGene Bio-Medical Technology Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
PP&E Gross
ÂĄ2.5B
CAGR 3-Years
61%
CAGR 5-Years
62%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
PP&E Gross
ÂĄ3.3B
CAGR 3-Years
-2%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
PP&E Gross
ÂĄ854.4m
CAGR 3-Years
12%
CAGR 5-Years
26%
CAGR 10-Years
11%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
PP&E Gross
ÂĄ7B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
PP&E Gross
ÂĄ3.6B
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
8%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
PP&E Gross
ÂĄ534.8m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.

Intrinsic Value
22.57 CNY
Overvaluation 29%
Intrinsic Value
Price

See Also

What is BrightGene Bio-Medical Technology Co Ltd's PP&E Gross?
PP&E Gross
2.5B CNY

Based on the financial report for Dec 31, 2023, BrightGene Bio-Medical Technology Co Ltd's PP&E Gross amounts to 2.5B CNY.

What is BrightGene Bio-Medical Technology Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
62%

Over the last year, the PP&E Gross growth was 16%. The average annual PP&E Gross growth rates for BrightGene Bio-Medical Technology Co Ltd have been 61% over the past three years , 62% over the past five years .

Back to Top